advertisement
11.4 Prostaglandins (14)
Showing records 1 to 14
Display all abstracts in classification 11.4 Prostaglandins
Search within classification 11.4 Prostaglandins50403 An Evaluation of Therapeutic Noninferiority of 0.005% Latanoprost Ophthalmic Solution and Xalatan in Patients With Glaucoma or Ocular Hypertension
Digiuni M; Manni G; Vetrugno M; Uva M; Milano G; Orzalesi N; Fogagnolo P; Centofanti M; Campos E; Rossetti L
Journal of Glaucoma 2013; 22: 707-712
50465 Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
Pfennigsdorf S; Ramez O; von Kistowski G; Mä,der B; Eschstruth P; Frobö,se M; Thelen U; Spraul C; Schnober D; Cooper H; Laube T
Clinical Ophthalmology 2012; 6: 739-746
50462 Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
Ermiş SS
Clinical Ophthalmology 2012; 6: 673-678
50541 Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
Pacella F; Turchetti P; Santamaria V; Impallara D; Smaldone G; Brillante C; Librando A; Damiano A; Pecori-Giraldi J; Pacella E
Clinical Ophthalmology 2012; 6: 811-815
50550 Intraocular Pressure-reducing Effects of Latanoprost Versus Timolol in Chinese Patients With Chronic Angle-closure Glaucoma
Zhao J; Ge J; Sun X; Wang N
Journal of Glaucoma 2013; 22: 591-596
50314 Intraocular Pressure-Lowering Effect of 0.005% Latanoprost with 2 Different Dosing Regimens
Nilforushan N; Naghibi A; Shokrollahi S; Soltan Sanjari M; Nouri-Mahdavi K
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 524-528
50415 A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 micro g/mL to latanoprost 50 micro g/mL (Xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension
Eveleth DD; Tressler CS; Starita C
BMC Ophthalmology 2012; 12: 9
49983 Lack of association between polymorphisms in the prostaglandin F(2α) receptor and solute carrier organic anion transporter family 2A1 genes and intraocular pressure response to prostaglandin analogs
McCarty CA; Berg R; Patchett R; Wilke RA; Burmester JK
Ophthalmic Genetics 2012; 33: 74-76
50413 A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients
Ranno S; Sacchi M; Brancato C; Gilardi D; Lembo A; Nucci P
TheScientificWorldJournal 2012; 2012: 804730
50378 Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy
Kashiwagi K
Japanese Journal of Ophthalmology 2012; 56: 339-345
50464 Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
Costa VP; Moreira H; Paolera MD; de Moraes Silva MR
Clinical Ophthalmology 2012; 6: 699-706
50490 A Comparative Study of a Preservative-Free Latanoprost Cationic Emulsion (Catioprost(®)) and a BAK-Preserved Latanoprost Solution in Animal Models
Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 515-523
50525 Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients
Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
Expert Opinion on Drug Safety 2012; 11: 519-525
49960 A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia
Blume-Peytavi U; Lö,nnfors S; Hillmann K; Garcia Bartels N
Journal of the American Academy of Dermatology 2012; 66: 794-800
